Treatment
AssigneeUNION therapeutics A/S
InventorsMorten SOMMER, Rasmus TOFT-KEHLER, Anne Katrine TOFT-KEHLER, Mads JELLINGSOE, Philippe ANDRES
Life of this patent
Estimating the term…
Abstract
Inhalable compositions comprising niclosamide, or a pharmaceutically acceptable salt thereof, and polyethylene glycol; aerosols of the compositions; and the pulmonary administrations for use in the treatment of viral infections, for example respiratory viral infections.
Claims91
An inhalable pharmaceutical composition comprising niclosamide, or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment of a viral infection in a subject, wherein the niclosamide, or a pharmaceutically acceptable salt thereof, is administered to the subject by inhalation.
A method for preventing or treating a viral infection is a subject, the method comprising administering to the subject by inhalation an effective amount of an inhalable pharmaceutical composition comprising niclosamide, or a pharmaceutically acceptable salt thereof.
An aerosol of a solution comprising niclosamide, or a pharmaceutically acceptable salt thereof.
An inhalable unit dosage comprising a solution of niclosamide, or a pharmaceutically acceptable salt thereof, and PEG, wherein niclosamide is present in an amount of from 1 mg to 600 mg based on the weight of niclosamide, for example from about 150 mg to about 500 mg, based on the weight of niclosamide.
An inhalable unit dosage comprising a solution of niclosamide ethanolamine and PEG, wherein niclosamide ethanolamine is present in an amount of from 2 mg to 600 mg, for example from about 150 mg to about 500 mg.
A system comprising a container comprising a solution of niclosamide, or a pharmaceutically acceptable salt thereof, and polyethylene glycol (PEG);
- and an inhaler device and/or an intranasal delivery device.
A kit comprising a container comprising a solution of niclosamide, or a pharmaceutically acceptable salt thereof, and polyethylene glycol (PEG);
- and an inhaler device and/or an intranasal delivery device.
An inhalable solution comprising from about 1% to 10% by weight niclosamide ethanolamine and PEG, wherein the PEG has an average molecular weight of less than 600;
- and optionally a taste-masking agent.
The composition for use or method according to any preceding claim, wherein the composition is for use in the treatment of a viral infection in an asymptomatic subject, optionally wherein the viral infection is SARS-CoV-2.
The composition for use or method according to any preceding claim, wherein the treatment is for:
- reducing or eliminating the viral load in the subject;
- accelerating seroconversion in the subject;
- reducing inter-subject transmission of the viral;
- reducing viral shedding;
- preventing or reducing the risk of the subject developing symptoms;
- and/or
- preventing or reducing the risk of progression of disease.
The composition for use or method according to any preceding claim, wherein the composition is administered intranasally.
Dependencies are inferred from the claim text.